Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Buy
58
ENFN Quote, Financials, Valuation and Earnings
Last price:
$10.54
Seasonality move
:
-3.43%
Day range:
$10.43 - $10.65
52-week range:
$7.52 - $11.38
Dividend yield:
0%
P/E ratio:
263.00x
P/S ratio:
6.40x
P/B ratio:
14.20x
Volume:
585.8K
Avg. volume:
496.6K
1-year change:
8.68%
Market cap:
$992.8M
Revenue:
$174.5M
EPS (TTM):
$0.04
Analysts' Opinion
-
Consensus RatingEnfusion has received a consensus rating of Hold. The company's average rating is a Hold based on 2 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $9.89, Enfusion has an estimated downside of -5.97% from its current price of $10.52.
-
Price Target UpsideAccording to analysts, the highest upside price target is $11.50 representing 9.32% upside increase from its current price of $10.52.
Fair Value
-
According to the consensus of 5 analysts, Enfusion has -5.97% downside to fair value with a price target of $9.89 per share.
ENFN vs. S&P 500
-
Over the past 5 trading days, Enfusion has underperformed the S&P 500 by -2.63% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Enfusion does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Enfusion has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Enfusion reported revenues of $51.2M.
Earnings Growth
-
Enfusion has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Enfusion reported earnings per share of $0.02.
Enterprise value:
970.7M
EV / Invested capital:
10.09x
Price / LTM sales:
6.40x
EV / EBIT:
144.78x
EV / Revenue:
4.97x
PEG ratio (5yr expected):
--
EV / Free cash flow:
46.07x
Price / Operating cash flow:
59.28x
Enterprise value / EBITDA:
51.84x
Gross Profit (TTM):
$131.1M
Return On Assets:
2.88%
Net Income Margin (TTM):
1.7%
Return On Equity:
3.97%
Return On Invested Capital:
3.97%
Operating Margin:
5.83%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $141.7M | $168.6M | $195.2M | $44.4M | $51.2M | |
| Gross Profit | $97.7M | $113.3M | $131.1M | $29.9M | $34.8M | |
| Operating Income | -$305.8M | $11.2M | $6.7M | $2.7M | $3M | |
| EBITDA | -$299.9M | $19.3M | $18.7M | $5.2M | $5.9M | |
| Diluted EPS | -$2.37 | $0.08 | $0.04 | $0.02 | $0.02 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $35.5M | $96M | $62M | $85.4M | |
| Total Assets | -- | $49.6M | $115.6M | $101.7M | $134.9M | |
| Current Liabilities | -- | $16.3M | $12M | $16.4M | $23.6M | |
| Total Liabilities | -- | $279.3M | $12.4M | $28.5M | $38.8M | |
| Total Equity | -- | -$229.6M | $103.2M | $73.3M | $96.2M | |
| Total Debt | -- | $97.5M | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $823K | $26.6M | $31.6M | $12.1M | $16.2M | |
| Cash From Investing | -$7.8M | -$9.1M | -$13.5M | -$2.6M | -$2.8M | |
| Cash From Financing | $62.5M | -$49.5M | -$2M | -$5.3M | -$14K | |
| Free Cash Flow | -$7M | $17.4M | $21.1M | $9.5M | $13.4M | |
ENFN
Sector
Market Cap
$992.8M
$115.4M
Price % of 52-Week High
92.48%
67.8%
Dividend Yield
0%
0%
Shareholder Yield
--
1%
1-Year Price Total Return
8.68%
-6.36%
Beta (5-Year)
--
0.944
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$10.65
200-day SMA
Buy
Level
$9.12
Bollinger Bands (100)
Buy
Level
8.26 - 9.96
Chaikin Money Flow
Sell
Level
-3.2M
20-day SMA
Buy
Level
$10.38
Relative Strength Index (RSI14)
Buy
Level
56.66
ADX Line
Sell
Level
19.93
Williams %R
Neutral
Level
-60.424
50-day SMA
Buy
Level
$9.71
MACD (12, 26)
Buy
Level
0.27
25-day Aroon Oscillator
Buy
Level
84
On Balance Volume
Neutral
Level
17.5M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (16.6129)
Buy
CA Score
(Annual)
Level (0.6324)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (6)
Buy
Ohlson Score
Level (-2.8787)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Enfusion Inc is a software-as-a-service (SaaS) provider focused on transforming the investment management industry. Its solutions are designed to eliminate technology and information barriers, empowering investment managers to make and execute an informed investment decisions in real-time. It simplifies investment and operational workflows by unifying mission-critical systems and coalescing data into a single dataset resulting in a single source of truth. It generates maximum revenue from Americas, followed by Asia Pacific and Europe, Middle East, and Africa.
Stock Forecast FAQ
In the current month, ENFN has received 2 Buy ratings 3 Hold ratings, and 0 Sell ratings. The ENFN average analyst price target in the past 3 months is $9.89.
-
Where Will Enfusion Stock Be In 1 Year?
According to analysts, the consensus estimate is that Enfusion share price will drop to $9.89 per share over the next 12 months.
-
What Do Analysts Say About Enfusion?
Analysts are divided on their view about Enfusion share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Enfusion is a Sell and believe this share price will rise from its current level to $8.00.
-
What Is Enfusion's Price Target?
The price target for Enfusion over the next 1-year time period is forecast to be $9.89 according to 5 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is ENFN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Enfusion is a Hold. 3 of 5 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of ENFN?
You can purchase shares of Enfusion via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Enfusion shares.
-
What Is The Enfusion Share Price Today?
Enfusion was last trading at $10.54 per share. This represents the most recent stock quote for Enfusion. Yesterday, Enfusion closed at $10.52 per share.
-
How To Buy Enfusion Stock Online?
In order to purchase Enfusion stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is down 8.7% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is up 9.77% over the past day.
Sell
48
VRNA alert for Dec 24
Verona Pharma PLC [VRNA] is up 7.96% over the past day.
